Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Cogent Biosciences (Nasdaq: COGT), a biotechnology company specializing in precision therapies for genetically defined diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Andrew Robbins, President and CEO, will deliver a presentation on Tuesday, January 14, 2025, at 7:30 a.m. PT/10:30 a.m. ET. The presentation will be accessible via live webcast on the company's Investors & Media webpage, with a replay available for 30 days following the event.
Cogent Biosciences (Nasdaq: COGT), un'azienda biotecnologica specializzata in terapie di precisione per malattie geneticamente definite, ha annunciato la sua partecipazione alla 43esima Conferenza Sanitaria Annuale J.P. Morgan a San Francisco. Andrew Robbins, Presidente e CEO, terrà una presentazione martedì 14 gennaio 2025, alle 7:30 ora del Pacifico/10:30 ora dell'Est. La presentazione sarà accessibile tramite webcast dal vivo sulla pagina web Investitori & Media dell'azienda, con una registrazione disponibile per 30 giorni dopo l'evento.
Cogent Biosciences (Nasdaq: COGT), una empresa de biotecnología especializada en terapias de precisión para enfermedades definidas genéticamente, anunció su participación en la 43ª Conferencia Anual de Salud J.P. Morgan en San Francisco. Andrew Robbins, Presidente y CEO, ofrecerá una presentación el martes 14 de enero de 2025, a las 7:30 a.m. PT/10:30 a.m. ET. La presentación estará disponible a través de un webcast en vivo en la página web de Inversores y Medios de la empresa, con una repetición disponible durante 30 días tras el evento.
Cogent Biosciences (Nasdaq: COGT)는 유전적으로 정의된 질병에 대한 정밀 치료를 전문으로 하는 생명공학 회사로, 샌프란시스코에서 열리는 제43회 J.P. Morgan 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 앤드류 로빈스 사장 겸 CEO는 2025년 1월 14일 화요일 오전 7시 30분 PT/오전 10시 30분 ET에 발표를 진행할 예정입니다. 이 발표는 회사의 투자자 및 미디어 웹페이지에서 라이브 웹캐스트를 통해 확인할 수 있으며, 행사 이후 30일 동안 다시 볼 수 있는 재생이 제공될 예정입니다.
Cogent Biosciences (Nasdaq: COGT), une entreprise de biotechnologie spécialisée dans les thérapies de précision pour les maladies génétiquement définies, a annoncé sa participation à la 43e Conférence Annuelle des Soins de Santé J.P. Morgan à San Francisco. Andrew Robbins, Président et CEO, donnera une présentation le mardi 14 janvier 2025, à 7h30 PT/10h30 ET. La présentation sera accessible en direct via un webcast sur la page Investisseurs & Médias de l'entreprise, avec un replay disponible pendant 30 jours après l'événement.
Cogent Biosciences (Nasdaq: COGT), ein Biotechnologieunternehmen, das sich auf Präzisionstherapien für genetisch definierte Krankheiten spezialisiert hat, gab seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz in San Francisco bekannt. Andrew Robbins, Präsident und CEO, wird am Dienstag, den 14. Januar 2025, um 7:30 Uhr PT/10:30 Uhr ET eine Präsentation halten. Die Präsentation wird über einen Live-Webcast auf der Webseite der Investoren und Medien des Unternehmens zugänglich sein, und eine Aufzeichnung wird 30 Tage nach der Veranstaltung zur Verfügung stehen.
- None.
- None.
WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 7:30 a.m. PT/10:30 a.m. ET.
A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.
Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653
FAQ
When is Cogent Biosciences (COGT) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch COGT's presentation at the J.P. Morgan Healthcare Conference?
Who will represent COGT at the 2025 J.P. Morgan Healthcare Conference?
How long will COGT's J.P. Morgan Healthcare Conference presentation replay be available?
